Moreau Maxim, Lussier Bertrand, Pelletier Jean-Pierre, Martel-Pelletier Johanne, Bédard Christian, Gauvin Dominique, Troncy Eric
Research Group in Animal Pharmacology of Quebec (GREPAQ), Department of Veterinary Biomedical Sciences - Faculty of Veterinary Medicine, Université de Montréal, P.O. Box 5000, Saint-Hyacinthe, Quebec J2S 7C6, Canada; Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Tour Viger, 900 St-Denis Street, Montreal, Quebec H2X 0A9, Canada.
Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Tour Viger, 900 St-Denis Street, Montreal, Quebec H2X 0A9, Canada.
Res Vet Sci. 2014 Dec;97(3):574-81. doi: 10.1016/j.rvsc.2014.09.011. Epub 2014 Sep 28.
An oral herb-based natural health product (NHP) was evaluated in the canine natural osteoarthritis model. At baseline, the peak vertical force (PVF, primary endpoint) and case-specific outcome measure of disability (CSOM) were recorded in privately-owned dogs. Dogs (16/group) were randomized to receive NHP formulations or a negative control. The PVF was measured at week (W) 4 and W8. Daily locomotor activity was recorded using accelerometer. The CSOMs were assessed bi-weekly by the owner. The NHP-treated dogs (n = 13) had higher PVF at W4 (p = 0.020) and W8 (p <0.001) when compared to baseline. The changes at W8 were higher than control dogs (n = 14, p <0.027) and consistent with Cohen's d effect size of 0.7 (95% confidence interval: 0.0-1.5). The NHP-treated dogs had higher locomotor activity at W8 (p = 0.025) when compared to baseline. No significant change was observed for the CSOM. The NHP improved the clinical signs of osteoarthritis in this model.
一种基于草药的口服天然健康产品（NHP）在犬类自然骨关节炎模型中进行了评估。在基线时，记录了私人拥有犬只的垂直峰值力（PVF，主要终点）和特定病例的残疾结局指标（CSOM）。犬只（每组16只）被随机分配接受NHP制剂或阴性对照。在第4周（W4）和第8周（W8）测量PVF。使用加速度计记录每日运动活动。主人每两周对CSOM进行评估。与基线相比，接受NHP治疗的犬只（n = 13）在W4时PVF更高（p = 0.020），在W8时更高（p < 0.001）。W8时的变化高于对照犬只（n = 14，p < 0.027），且与Cohen's d效应量0.7一致（95%置信区间：0.0 - 1.5）。与基线相比，接受NHP治疗的犬只在W8时运动活动更高（p = 0.025）。CSOM未观察到显著变化。在该模型中，NHP改善了骨关节炎的临床症状。
